EP1267864A1 - Formulation synergetique anti-paludique - Google Patents
Formulation synergetique anti-paludiqueInfo
- Publication number
- EP1267864A1 EP1267864A1 EP00940733A EP00940733A EP1267864A1 EP 1267864 A1 EP1267864 A1 EP 1267864A1 EP 00940733 A EP00940733 A EP 00940733A EP 00940733 A EP00940733 A EP 00940733A EP 1267864 A1 EP1267864 A1 EP 1267864A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formulation
- rectal
- arteether
- treatment
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 162
- 238000009472 formulation Methods 0.000 title claims abstract description 150
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 7
- 230000000078 anti-malarial effect Effects 0.000 title description 11
- 239000003430 antimalarial agent Substances 0.000 title description 10
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims abstract description 62
- 201000004792 malaria Diseases 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 27
- NLYNIRQVMRLPIQ-LTLPSTFDSA-N 10-ethoxydecahydro-3,6,9-trimethyl-(3r,5as,6r,8as,9r,10r,12r,12ar)-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-LTLPSTFDSA-N 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 16
- 239000008158 vegetable oil Substances 0.000 claims abstract description 16
- 206010010071 Coma Diseases 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 12
- 230000002490 cerebral effect Effects 0.000 claims abstract description 7
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 45
- 229940079593 drug Drugs 0.000 claims description 44
- 229960002970 artemotil Drugs 0.000 claims description 33
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 30
- 239000000829 suppository Substances 0.000 claims description 27
- 239000003921 oil Substances 0.000 claims description 25
- 235000019198 oils Nutrition 0.000 claims description 25
- 241000223960 Plasmodium falciparum Species 0.000 claims description 24
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 23
- 229960000948 quinine Drugs 0.000 claims description 23
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 229960001962 mefloquine Drugs 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 239000004098 Tetracycline Substances 0.000 claims description 19
- 229960002180 tetracycline Drugs 0.000 claims description 19
- 235000019364 tetracycline Nutrition 0.000 claims description 19
- 229930101283 tetracycline Natural products 0.000 claims description 19
- 150000003522 tetracyclines Chemical class 0.000 claims description 19
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 18
- 229960003677 chloroquine Drugs 0.000 claims description 18
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 18
- 244000045947 parasite Species 0.000 claims description 18
- 229960004991 artesunate Drugs 0.000 claims description 17
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 17
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims description 16
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 14
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 14
- 235000019483 Peanut oil Nutrition 0.000 claims description 12
- 239000000312 peanut oil Substances 0.000 claims description 12
- 241001442535 Plasmodium yoelii nigeriensis Species 0.000 claims description 11
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims description 9
- 229960000611 pyrimethamine Drugs 0.000 claims description 9
- 229960000901 mepacrine Drugs 0.000 claims description 8
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 239000004100 Oxytetracycline Substances 0.000 claims description 7
- 229960000981 artemether Drugs 0.000 claims description 7
- 229960004191 artemisinin Drugs 0.000 claims description 7
- 229930101531 artemisinin Natural products 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 7
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 7
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 229960003276 erythromycin Drugs 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 7
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 7
- 229960001180 norfloxacin Drugs 0.000 claims description 7
- 229960000625 oxytetracycline Drugs 0.000 claims description 7
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 7
- 235000019366 oxytetracycline Nutrition 0.000 claims description 7
- 229960005179 primaquine Drugs 0.000 claims description 7
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 7
- 229960001404 quinidine Drugs 0.000 claims description 7
- 239000006215 rectal suppository Substances 0.000 claims description 7
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229960003722 doxycycline Drugs 0.000 claims description 6
- 229960004673 sulfadoxine Drugs 0.000 claims description 6
- -1 amodoquine Chemical compound 0.000 claims description 5
- 229960003405 ciprofloxacin Drugs 0.000 claims description 5
- 230000001445 schizonticidal effect Effects 0.000 claims description 5
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 4
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 4
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 4
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 4
- 229960001444 amodiaquine Drugs 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229960002398 demeclocycline Drugs 0.000 claims description 4
- 230000000646 gametocidal effect Effects 0.000 claims description 4
- 229960003242 halofantrine Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- DJUFPMUQJKWIJB-UHFFFAOYSA-N pyronaridine Chemical compound C12=NC(OC)=CC=C2N=C2C=C(Cl)C=CC2=C1NC(C=C(CN1CCCC1)C=1O)=CC=1CN1CCCC1 DJUFPMUQJKWIJB-UHFFFAOYSA-N 0.000 claims description 4
- 229950011262 pyronaridine Drugs 0.000 claims description 4
- LBHLFPGPEGDCJG-UHFFFAOYSA-N N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine Chemical compound COC=1C=C(NC(C)CCCN)C2=NC(OC)=CC(C)=C2C=1OC1=CC=CC(C(F)(F)F)=C1 LBHLFPGPEGDCJG-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940100618 rectal suppository Drugs 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 230000000630 rising effect Effects 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 230000001568 sexual effect Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 108010061951 Methemoglobin Proteins 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 231100000820 toxicity test Toxicity 0.000 claims description 2
- 241000224016 Plasmodium Species 0.000 claims 3
- 244000269722 Thea sinensis Species 0.000 claims 1
- 235000013616 tea Nutrition 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 23
- 206010063094 Cerebral malaria Diseases 0.000 description 7
- 240000009188 Phyllostachys vivax Species 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 210000000973 gametocyte Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000035999 Recurrence Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 2
- 208000002476 Falciparum Malaria Diseases 0.000 description 2
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000224028 Plasmodium cynomolgi Species 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 229960002521 artenimol Drugs 0.000 description 1
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229930016266 dihydroartemisinin Natural products 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229930183339 qinghaosu Natural products 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to novel synergistic formulation comprising ⁇ , ⁇ -arteether together with vegetable oil, said formulation useful in the treatment of comatose and cerebral malarial cases.
- the formulation specifically useful for rectal route treatment of highly multi-drug resistant P. falciparum and P. vivax cases and which can be used for emergency treatment of comatose and cerebral malaria.
- the invention also provides methods of treatment of malaria affecting the brain employing the novel formulation.
- the invention also provides process for preparation of the said novel formulation.
- Mefloquine was reported to produce neuropsychiatric side-effects in adults who developed tonic clonic fits. Besides psychosis, delusions and hallucinations, anxiety sleep disturbances were also reported after mefloquine (Drugs 1990, 39, 160-169).
- Multi-drug-resistance in P. falciparum malaria and high level of P. vivax resistant strains are posing a major threat to countries in South-east Asia. Africa and Southern America. Most seriously affected areas include Thai-Myanmar Burmese border, where resistance to nearly all available drugs (Chlorquine, sulfadoxine-pyrimethamine, mefloquine, quinine) has already got established, (WHO Report on Infectious Diseases, 1999, WHO/CDS/99 1)
- Halofant ⁇ ne ts more effective but rather high doses of the drug are now required to control resistant P. falciparum (Brasseur et al 1993 Lancet 341, 901-2) which cold lead to increased risk of cardiotoxicity of this new antimalarial including sinus bradycardia, sinus arrhythmia, tall peak T waves, QT interval prolongation, ectopic beats (Karbwang et al 1993, Lancet, 342, 501, Wildling et al 1993 Lancet, 342, 55, Kremsner et al Am J Trop Med Hyg 50, 790-795) which has imposed great limitation on the antimalarial potential of this drug Several reports have recently appeared which document emergence of chloroquine resistance by P.
- ⁇ , ⁇ -arteether is an ethylether derivative of qinghaosu (artemisinine), which is extracted from Artemisia anniia, a plant long known in traditional Chinese medicine for its antimalarial properties
- ⁇ , ⁇ -Arteether (30 70) is one of the artemisinin derivatives that has been developed in India and shows antimalarial activity against chloroquine, mefloquine and quinine resistant P. yoeln mgenensis and cures experimental cerebral malaria infections P. knowlesilP.
- ⁇ / ⁇ -Arteether is relatively safer and its LD 50 dose is 1250 mg/kg in Swiss mice as compared to artemether (LD 50 263 mg/kg (im) and artesunate (LD50 475 mg/kg, im)(J Trad Chinese Med 1982,2(1) 31-38).
- Clinical trials of intramuscular injection of this compound have been completed and marketed Data on clinical trials with injectible preparation of ⁇ , ⁇ arteether (30 70 mixtures of isomers amongst P. falciparum cases has been published (Mohapatra et al 1996 Indian J Med Res 104, 284-7, Nalecha et al 1997, Int J Clin Pharm Res XNII (1) 11-15 Mohanty et al 1997 Trans. R Soc Trop Med Hyg 91, 328-330, Mishra et / 1995, Trans R Soc. Trop Med Hyg 89, 299-301)
- the main objective of the present invention is to provide a useful synergistic formulation of ⁇ , ⁇ -arteether for treatment of cerebral malaria.
- Another objective of the present invention is to provide a formulation which is highly effective, easy to use, non-messy and non-cumbersome and can be administered by the rectal route to control cerebral malaria and which can also be used to clear a wide spectrum of infections resistant to most of the conventional antimalarials, antibiotic and other drug combinations.
- Another objective of the invention is to provide a formulation effective in controlling malarial parasites in both asexual and sexual stages, in both drug sensitive and resistant malaria infections.
- Yet another objective is to provide the rectal arteether can be effective in stopping malaria transmission and spread of the disease.
- the present invention relates to a synergistic formulation comprising ⁇ / ⁇ arteether useful for the treatment of wide spectrum multi-drug resistant malaria and emergency treatment of comatose malaria
- the formulation can be administered in malarial cases by rectal route in the form of rectal formulation, suppository in different doses form for infant, children, adults and pregnant woman
- the above said formulation can be given by oral route also, for complete elimination of malaria infection.
- the formulation would be effective in stopping the malarial transmission.
- the invention also provides a process for the preparation of the said formulation
- the invention provides a synergistic formulation comprising pharmaceutically effective amount of ⁇ / ⁇ arteether and a neutralized refined vegetable oil suitable for administration by rectal route
- the vegetable oil is sterilized neutral refined oil that does not solidify in winter at room temperature
- the ratio of ⁇ / ⁇ arteether and vegetable oil in the formulation is 0 002-0 020 1 w/w, preferably 0 0025 1 w/w
- the vegetable oil is selected from the group comprising ground nut oil, sesame oil and tea oil.
- ⁇ and ⁇ tautomers are present in a ratio of 10 90 to 30 70 In still another embodiment, the preferred ratio of ⁇ and ⁇ tautomers in the formulation is 30:70.
- the formulation is used against a wide spectrum of Plasmodium yoelii nigeriensis (MDR II) parasite resistant to high oral doses of drugs selected from chloroquine, amodoquine, mepacrine, mefloquine, quinine, quinidine, pyrimethamine, pyronaridine, halofantrine, pyrimethamine+sulfadoxin, primaquine and WR 238605.
- MDR II Plasmodium yoelii nigeriensis
- the formulation is used against Plasmodium yoelii nigeriensis resistant to antibiotics selected from tetracycline, oxytetracycline, demeclocycline, erythromycin, ciprofloxacine, norfloxacine and doxycycline.
- Plasmodium yoelii nigeriensis resistant to antimalarial-antibiotic combinational drugs selected from chloroquine +tetracycline, amodiaquine+tetracycline, mefloquine+tetracycline, mepacrine+tetracycline, quinine+tetracycline, quinine+oxytetracycline, quinine+doxycycline, quinine+erythromycin, cyprofloxacine +chloroquine, norfloxacine+chloroquine and quinine+tetracycline.
- the said formulation is viscous and light yellow in colour.
- the ⁇ and ⁇ tautomers in the formulation are present in a ratio of 10:90 to 30:70. and maintains longer half life (22 hrs or more).
- the same formulation can also be made into regular rectal suppository which can be administered into rectum 3-4 times daily during acute phase of malaria.
- the formulation can be used as substitute of primaquine and WR236805 and useful for interrupting transmission of P. falciparum because of its gametocytocidal action.
- the formulation has a half life of about 22 hrs or more.
- the formulation provides extended bioavailability because of longer T 1/2 ⁇ (clearance) in comparison to other artemisinin derivatives such as artemether or artesunate which have short plasma half life.
- the formulation shows no adverse gastric effects, hemorrhage etc. which are found in the rectal or oral treatment with other artemisinin derivatives in tablet form.
- the formulation is safe (LDso > 1250 mg/kg), well tolerated and much safer than artemether and artesunate in animal toxicity tests.
- the formulation can be administered by rectal or oral routes or as gelatin capsule, given three to four times daily, and the formulation has shelf life of more than three years.
- the formulation has 100-300 times more accumulation in the malarial infected red blood cells than the normal red blood cells.
- the said formulation has adequate rectal absorption of compound sufficient to arrest the rising parasitaemia and the treated animals show significant reduction/clearance of parasitaemia indicating sufficient rectal drug absorption.
- the formulation has blood schizontocidal activity as useful for the emergency treatment of uncomplicated severe complicated/cerebral and multi-drug resistant malarial infections including comatose malaria cases (for which it is the first line of emergency treatment).
- the said formulation has no adverse met-hemoglobin type of toxicity which is known to be associated with administration of primaquine and WR236805.
- the invention provides methods for the treatment of comatose cerebral malarial conditions comprising the steps of rectal administration of the formulation to a subject in need thereof.
- the formulation is effective against sexual stage of parasites selected from P. falciparum, P. vivax and P. cynomolgi.
- the formulation for rectal/oral treatment is used in the form of rectal formulation rectal suppositories/ oral gelatin capsules of liquid formulations in different dose forms for infants, children and adults.
- the formulation is effective and safe in pregnant malaria infected monkeys, and could be useful for treatment of severe malaria in pregnant women.
- the formulation is administered by the rectal route in children as well as adults for longer periods of once or twice a week until transmission continues
- the process for the preparation of a formulation useful for the control of wide spectrum of malaria comprising (a) preparation of arteether ⁇ and ⁇ from artemisinin by known methods, (b) dissolving ⁇ / ⁇ arteether in sterilized neutral refined vegetable oil heating at 70-90°C for 2-4 min. and (c) cooling the solution at room temperature to obtain the desired formulation and (d) followed by sterilization of formulation by filtration through 0.45 ⁇ m filter.
- the major advantage of the arteether rectal formulation will be to treat very serious cases/ comatose cases of cerebral malaria with a view to reduce mortality among P. falciparum cases particularly in children, pregnant women who are at maximum risk and can prove fatal unless the emergency therapy is instituted.
- a still another advantage of the rectal formulation of arteether will be to control multi-drug resistant infections due primarily to P. falciparum which because of problem of resistance can not be treated effectively or cured with conventional antimalarial drugs such as chloroquine, mefloquine, amodiaquine, mepacrine, quinine, quinidine, halofantrin, pyrimethhamine, pyronaridine, WR238605 to which the parasite might be resistant, or with standard suppressive antimalarial antibiotics such as tetracycline, oxytetracycline, demeclocycline, doxycycline, erythromycin, ciprofloxacin, norfloxacin to which plasmodia may be resistant or with diverse antimalarial+antibiotic combination such as chloroquine, amodiquine/ mefloquine/ mepacrine/ quinine/ quinidine+tetracycline combinations or quinine/ quinidine+oxytetracycline combination, or qui
- Another advantage of formulation will be to control chloroquine resistant P. vivax blood infections which are presently spreading in many continents could be effectively treated initially with rectal arteether formulation to prevent deterioration of the condition of the patient, and as soon as the patient is brought to the hospital arteether formulation can also be given parenterally as intramuscular (3 doses) curative treatment. All cases of P. falciparum and P. vivax which need a life saving therapy/those in coma /serious complicated P.
- infants can be administered rectal arteether formulations 2-4 times daily to revive the comatose cases and rectal therapy used as emergency treatment can be changed to parenteral (oral) therapy with same arteether formulation (prepared in neutralized oil) which allows rapid drug absorption from gut and can provide effective control of parasitaemia, by oral route.
- Rectal suppositories are simple to administer, easy to store at room temperature and administered, as it does not require any special equipment and can be given as emergency drug at rural health centers throughout the developing world. Suppository could be used in remote areas/villages incases who might not survive the long journey or delay in reporting to the hospital.
- the formulation ( ⁇ / ⁇ -arteether and vehicle) is relatively safe as compared to other artemisinin derivatives (LDj 0 in mice>1250 mg/kg) and consequently the therapeutic index is more favorable for treatment of malaria.
- the neutralized refined oil thus prepared was superior to commercial refined oil because it was stable even during winter on the shelf and did not solidify during overnight very low temperature. Accordingly, the present invention provides a process of the preparation of formulation useful for treatment of malaria, which comprises mixing 5 to 15% by weight of arteether with 85 to 95% by weight of neutralized refined ground nut oil which can be put into soft gelatin capsule for rectal treatment, or taking material in syringe and giving rectal administration of drug through a nozzle or catheter or prepare into standard suppository by known methods.
- ⁇ / ⁇ arteether used may be selected from the mixture in different proportions ranging from 10-30 of ⁇ - and 70-90 of ⁇ -isomers.
- the formulation used may be mixed with known suppository formulations such as glycerols substituted glycol, alkyl alcohol and mixture thereof.
- the resulting composition (formulation and standard suppository materials) may be molded into desired shape and size.
- the composition can also be made into a suppository like glycrine suppository or can be put in a soft gelatin capsule or the final formulations can be administered deep into rectum through plastic nozzle or rubber catheter 2-4 times daily for several days to reduce the parasitaemia to eliminate infection.
- Neutralized oil Refined ground nut oil was purchased from commercial source locally. 100 ml oil was taken in separating funnel and to this 50 ml of sterile 5% sodium bicarbonate solution was added and was shaken for 10 min thoroughly to mix sodium bicarbonate with the oil. This solution was allowed to stand for 2 hrs, sodium bicarbonate layer was drawn out and fresh bicarbonate was added and process was repeated for 4 times to prepare neutralized oil. Last bicarbonate washing was continued for over night and after bicarbonate treatment, washing with sterilized deionized distilled water was started and likewise 4 washing of the treated oil were given with 50 ml distilled water. After the last washing, oil was filtered through double layered Whattman filter no.
- Multi-drug resistant character of Plasmodium yoelii nigeriensis (MDR strain):
- mice weighing 20 ⁇ 1 to 25 ⁇ 1 g of either sex and random laboratory bred at Central Drug Research Institute, Lucknow were used. Mice were routinely infected with lxlO 3 parasitized RBC intraperitoneally using sterile citrate saline as diluent for infected blood
- the parasite suspension were inoculated in healthy mice by intraperitoneal route on day 0, and drugs were administered orally once a day for 4 doses (day 0 to day+ 3). From day 4 onwards, tail blood smears were examined after Giemsa staining and percent parasitaemia and mortality was recorded.
- the parasite (MDR strain) was lethal for Swiss mice and mice died in 6-8 days after developing parasitaemia above 40% to 100% infection of RBC. Mortality was 100% in mice.
- Table Present status of resistance pattern of P. yoelii nigeriensis (MDRII) strain to different antimalanals in Swiss mice.
- ⁇ , ⁇ -Arteether mixture dissolved in neutralized ground-nut oil was administered to P. yoelh nigeriensis (MDR II) infected mice at 10 mg/kg to 20 mg/kg dose from day 0 to day 2 (for 3 consecutive days) by intra-rectal route
- Drug was administered with 0 05-0 25 ml oil (vehicle) in single dose or in 2 divided dose daily
- Parasitaemia was recorded daily from tail blood smears stained with Giemsa stain and results are given as % parasitaemia (means ⁇ SD) All the doses of arteether namely 10 0, 15 0 and 20 0 mg/kg suppressed the parasitaemia even after treatment (upto 5 days) as shown by blood smear examination The study shows that till day 5, the control mice had developed very high level of parasitaemia (57 6 ⁇ 24 7) and had starting dying whereas the groups of mice administered 15-20 mg/kg ⁇ , ⁇ -arteether formulation by rectal route treatment were fully protected as shown
- Rectal formulation can easily control highly multi drug resistant malaria infections which do not respond to drugs like chloroquine, amodiaquine, mepacrine, mefloquine, halofantrine, quinine, quinidine, pyrimethamine +sulfadoxin etc. in MDR areas. Rectal route ⁇ / ⁇ arteether formulation remains 1 st line of emergency treatment of comatose P. falciparum cases in areas of MDR.
- Swiss mice 25 ⁇ 1 gm infected intraperitoneally with 1x10 parasitized rbcs were administered ⁇ / ⁇ formulation, prepared in DMSO (3-4 drop) and then suspended in distilled water by oral administration at various doses ranging between 40-100 mg/kg for 5 consecutive days
- Curative dose 60 mg/kg x 5 doses
- yoelii nigeriensis MDR II was achieved As discussed above the bioavailability of oral arteether ⁇ / ⁇ (powder) prepared into dosage form in DMSO and distilled water is of lower order and a dose of 60 mg/kg x 5 days is needed for multi-drug resistant P. yoelii nigeriensis (MDRII) total clearance, whereas oral arteether ( ⁇ / ⁇ ) formulation in neutralized refined ground nut oil is much more effective and 50% drug dose (30 mg/kg x 5) is effective in 100% parasite clearance. Thus formulation in oil is superior for treatment of malaria.
- P. falciparum clinical cases which were ganetocyte carriers were administered arteether formulation parenterally (intramuscular) at 150 mg dose (in neutralized ground nut oil) x 3 days for treatment of malaria, and within 48 h both asexual parasitaemia and gametocytes were completely cleared from the blood stream.
- 8 cases 7 cases were cleared of gametocytes within 24 h of treatment while in the 8 th case gametocytes were cleared by 48 h.
- the study shows strong gametocytocidal action of arteether formulation. All cases remained parasite free upto 28 days observation and drug cure rate was 100 percent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2000/000039 WO2001074353A1 (fr) | 2000-03-31 | 2000-03-31 | Formulation synergetique anti-paludique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1267864A1 true EP1267864A1 (fr) | 2003-01-02 |
Family
ID=11076239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00940733A Ceased EP1267864A1 (fr) | 2000-03-31 | 2000-03-31 | Formulation synergetique anti-paludique |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1267864A1 (fr) |
AU (1) | AU2000255631A1 (fr) |
WO (1) | WO2001074353A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040023897A1 (en) * | 2001-11-13 | 2004-02-05 | Caplan Michael J. | Methods for preventing or treating disease mediated by toxin-secreting bacteria |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68906345T2 (de) * | 1988-10-07 | 1993-10-28 | Hoechst Ag | Antimalariazusammenstellungen, gebrauchmachend von Quinidin, Artemisinin und ihren Derivaten. |
CN1058717A (zh) * | 1990-08-08 | 1992-02-19 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗疟新药—复方蒿甲醚及其制备方法 |
CH692321A5 (de) * | 1997-11-03 | 2002-05-15 | Mepha Ag | Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält. |
IN191696B (fr) * | 1999-02-12 | 2003-12-20 | Council Scient Ind Res |
-
2000
- 2000-03-31 AU AU2000255631A patent/AU2000255631A1/en not_active Abandoned
- 2000-03-31 WO PCT/IN2000/000039 patent/WO2001074353A1/fr active Application Filing
- 2000-03-31 EP EP00940733A patent/EP1267864A1/fr not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO0174353A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2000255631A1 (en) | 2001-10-15 |
WO2001074353A1 (fr) | 2001-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Looareesuwan et al. | A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand. | |
Qinghaosu | Antimalaria studies on Qinghaosu | |
Mishra et al. | Alkaloids: future prospective to combat leishmaniasis | |
CN1085527C (zh) | 增效复方抗疟药本芴醇的制备方法 | |
KR101512495B1 (ko) | 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 | |
EP1835921B1 (fr) | 9a-carbamoyl-y-aminopropyl- et 9a-thiocarbamoyl-y-aminopropyl-azalides a activite anti-paludique | |
Nosten et al. | New antimalarials: a risk-benefit analysis | |
US6326023B1 (en) | Synergistic anti-malarial formulation | |
Bunnag et al. | Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria | |
Thillainayagam et al. | Mosquito, malaria and medicines-A Review | |
CN1041694A (zh) | 奎尼丁、青蒿素及其衍生物的抗疟组合物和治疗方法 | |
JP3686281B2 (ja) | 広範囲のマラリア抑制のためのジヒドアルテミシニンの製剤およびその製造方法 | |
JPH08504403A (ja) | ニームノキから誘導される治療用化合物 | |
HU200688B (en) | Process for producing pharmaceutical composition against malaria | |
JPH0232093A (ja) | 抗レトロウィルスジフルオロ化ヌクレオシド類 | |
Caillard et al. | Plasmodium vinckei petteri: identification of the stages sensitive to arteether | |
EP1267864A1 (fr) | Formulation synergetique anti-paludique | |
TWI402071B (zh) | 用於治療嚴重瘧疾之雙噻唑鎓鹽或其前驅物與青蒿素或其衍生物之組合 | |
ZA200208485B (en) | A synergistic anti-malarial formulation. | |
Jadhav et al. | Retrospective Review of Chromane Analogues as Anti-protozoal Leads: A Decade's Worth of Evolution | |
Tripathi et al. | The Use of Artemisinin Derivative Suppositories as Life-Saving Remedy for Critical Malaria Patients | |
JP2021116291A (ja) | 2,4−ジアミノ−6,7−ジメトキシキナゾリン誘導体を有効成分として含有する医薬品組成物、及び特定の構造を有する2,4−ジアミノ−6,7−ジメトキシキナゾリン誘導体 | |
US5486535A (en) | Method for treating toxoplasmosis | |
WO1992007564A2 (fr) | Procede de traitement des maladies demyelinisantes | |
US20060141024A1 (en) | Synergistic combination kit of alpha,beta-arteether, sulfadoxin and pyrimethamine for treatment of severe/multi-drug resistant cerebral malaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021007 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20041026 |
|
17Q | First examination report despatched |
Effective date: 20041026 |
|
APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20100408 |